Evidence map›Paper›PMID 39861693›Full record

ArticlePharmaceutics2025

Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy.

Yanru Feng, Xintong Pan, Ziqian Li, Yue Li, Ya'nan Sun, Shaokun Yang, Chaoxing He, Yunjie Dang, Lu Huang, Bai Xiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanru FengDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Xintong PanDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Ziqian LiDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Yue LiDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Ya'nan SunDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Shaokun YangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Chaoxing HeDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Yunjie DangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Lu HuangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Bai XiangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.ORCID 0000-0002-4789-641X

Funding

Hebei Province Funding Project for Introduced Overseas Personnel C20220345Hebei Province Funding Project for Introduced Overseas Personnel C20230351National Natural Science Foundation of China 81302725National Natural Science Foundation of China 81973251Shijiazhuang Basic Research Project 241791397A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

co-deliveryhydroxychloroquinelipid nanoparticlerheumatoid arthritissiTNF-α

Identifiers

PMID39861693
PMCPMC11769357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.